nuke
Credits:
2237
My Scrapbook
My Reading List
1 Books
|
AFCAPS/TexCAPS Trial
|
07.23.05 (3 years ago)
#1
|
|
Air Force/Texas Coronary Atherosclerosis Prevention Study - AFCAPS/TexCAPS
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
The first primary prevention trial to report a clinical benefit in treating patients without clinically evident coronary heart disease and with average total and LDL-cholesterol, and below average HDL-cholesterol.
Study: The objective of the study was to compare lovastatin with placebo in prevention of the first acute major coronary event in men and women. The trial involved 6,605 patients, male mean age 57, female mean age 63, with no previous history of CHD, average total and LDL-cholesterol levels, and below average HDL-cholesterol. Patients were randomised to take a placebo or lovastatin (20 or 40 mg), once daily. The mean study follow up was 5.2 years, on average.
Key result: There was a significant 37% reduction in risk for first major coronary event with lovastatin as compared with placebo.
Reference: Downs, JR et al, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of the AFCAPS/TexCAPS. JAMA, 1998; 279: 1615-22
| dramh10 wrote: |
• AFCAPS/TEXCAPS
o The mean total cholesterol for the trial group (♂ & ♀) was 5.71 mmol/l.
o patients were randomized to lovostatin (20-40mg daily) or placebo in addition to a low cholesterol, low saturated fat diet
o after an average follow-up of 5.2 years
o the lovostatin group showed a significant reduction in incidence of acute major coronary events (by 37%), unstable angina (325) and myocardial infarctions (40%).
o the beneficial effects of lovostatin therapy were evident after only one year of the study.
o lovostatin group showed a reduction in LDL cholesterol by 25% and an increase in HDL cholesterol by 6%.
o Conclusions - lovostatin therapy reduced the risk of acute coronary artery events in a trial group with average total and LDL-cholesterols.Treatment benefits were apparent in men and women. |
|
|
|
Topic Tags: 
